Cardiovascular Health

In the phase 3 SURMOUNT-4 trial, investigators included individuals with at least 1 weight-related complication, including hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

Encouraging patients to take a proactive approach to their heart health can have great benefits

Investigators found that positive antiphospholipid antibodies and traditional risk factors were associated with atherosclerotic cardiovascular disease.

The study authors reported a 50% uptick in pharmacist prescribing was associated with approximately $1.137 trillion in savings over a 30-year time period.

These findings could make a significant difference in treating patients with Barth syndrome, which is an incurable genetic disease.

Investigators believe that the activation of mast cells drives inflammation and contributes to plaque buildup, causing heart attacks and other damage to the heart.

Artificial intelligence could help detect a trend in medical information for individuals that would help physicians predict an increased risk of sudden cardiac death.

A single infusion of VERVE-101, a gene editing tool, improved both blood PCSK9 protein levels and blood LDL-C levels in 10 individuals with high-risk HeFH.

The RESCUE BT2 trial sheds further light on the agent’s potential.

Session speaker Powell-Wiley explains how screening for SDOH in patients as cardiovascular-kidney-metabolic syndrome stages progress can help better understand their individual social needs.

Ince describes why patients who are considered fragile are often underdiagnosed and undertreated, and that the VOYAGER PAD analyses can encourage the treatment of the fragile population.

The AZALEA-TIMI 71 randomized trial evaluated the safety and tolerability of 2 blinded doses of the novel factor XI inhibitor abelacimab compared with open-label rivaroxaban.

Bonaca also notes that pharmacists can play a key role in educating patients and clinicians about the appropriate use and dosing of antithrombotic drugs for vascular protection.

Harrington discusses how the performance of milvexian in prior phase 2 trials focused on different patient populations creates the foundation for future research.

Sehnert emphasizes that mavacamten treatment benefits were present in both patients with sarcomere mutation positive HCM and sarcomere mutation negative HCM.

Clinically meaningful lowering of blood pressure through reduction in dietary sodium was achieved safely and rapidly in 1 week in a middle-aged and elderly cohort.

Elevated Lp(a), which was previously untreatable, may become treatable in the near future, according to the study investigator.

The SPRINT trial was the first to demonstrate the benefit of further reduction in blood pressure, but it included a limited Asian population and excluded patients with diabetes or history of stroke.

The SELECT trial expands on existing literature that have shown safety and cardiovascular benefit in individuals with diabetes to now also show benefit in obesity.

The American Heart Association published a statement describing the cardiovascular-kidney-metabolic (CKM) construct, specifically highlighting treatment challenges for CKM syndrome.

In most patients who are pregnant or may become pregnant, warfarin is contraindicated due to increased risk of adverse fetal outcomes.

An analysis of the REVOLUTIONIZE II study data showed that there is an unmet need for long-term outpatient treatment of hyperkalemia in patients with CKD.

How pharmacy teams can remove cost barriers to cardiac care.

Without policies to reduce greenhouse gas emissions, the number of cardiovascular-related deaths due to extreme heat could even triple by mid-century.

According to the authors, identifying the degree of disagreement with physicians’ deprescribing recommendations can improve the communication among older adults and their physicians.

Black men had 27% lower odds of an ideal cardiovascular health score compared to White men, whereas Black women had 55% lower odds compared to White women.

White-coat hypertension was diagnosed in 17 of 35 patients who completed out-of-office blood pressure monitoring.

The FDA has issued a Prescription Drug User Fee Act fate of March 26, 2024, for sotatercept (Merck) as treatment for adults with pulmonary arterial hypertension.

Cases highlight an acute subdural hematoma and chronic obstructive pulmonary disease.